A single gold dose-response SR+MA of prospective cohorts (Fang 2016, BMC Medicine): 40 publications / 70 reports, >1 million participants, 67,261 cases, 4-30 year follow-up, FFQ-assessed dietary magnesium (NOT supplements). It quantifies what a 100 mg/day higher dietary magnesium intake is associated with across six outcomes. (Fang et al., 2016)
The effect estimates — outcome-specific, not uniform
Per 100 mg/day higher dietary magnesium (relative risks; the analysis reports no absolute risks — absolute benefit scales with each stratum’s baseline risk, route (a), see Baseline Risk and the Relative-Absolute Split):
| Outcome | RR per +100 mg/day (95% CI) | Verdict |
|---|---|---|
| Type 2 diabetes | 0.81 (0.77-0.86) | benefit — largest and most robust |
| Heart failure | 0.78 (0.69-0.89) | benefit, but thin base (3 datasets / 2 cohorts) |
| Stroke | 0.93 (0.89-0.97) | benefit — ischemic-driven |
| All-cause mortality | 0.90 (0.81-0.99) | benefit — borderline, least robust |
| CHD | 0.92 (0.85-1.01) | no significant association per-increment |
| Total CVD | 0.99 (0.88-1.10) | no association |
The author summary: a 100 mg/day increase is associated with a 7% / 22% / 19% / 10% lower risk of stroke / heart failure / T2D / mortality, and no clear association with CHD or total CVD. (Fang et al., 2016)
Why the split matters: the outcome menu is not moved uniformly (as it never is — Surrogate Outcomes). T2D carries the strongest, largest-magnitude, tightest signal; total CVD is a clean null. A single magnesium is cardioprotective headline would erase that structure.
Curve shape — non-linearity is flagged but NOT located
Restricted-cubic-spline tests reject a purely linear model for CHD (P<0.05), stroke (P<0.001), T2D (P<0.001), and mortality (P<0.01); CVD shows no non-linearity (P=0.097). But the paper gives only a spline P-value and a figure — it does not locate a knee, threshold, or plateau in the text. Per the dose-response discipline, that is a non-linear shape is present over the studied range, not a minimum effective dose sits at X. No optimum is derivable here. (Fang et al., 2016)
- Studied ranges (the extrapolation boundary): roughly 100-550 mg/day across outcomes (CVD/T2D/mortality ~100-500; CHD ~150-450; stroke ~150-550). Any apparent flattening at the top edge is as likely the sampling boundary as a true plateau.
- The RDA (350 mg/day male, 300 mg/day female) is a deficiency-coverage construct — read it as a requirement floor, never as the optimum this curve implies; population intakes in EU/US surveys run below it. (Fang et al., 2016)
The binding uncertainty — is magnesium the lever, or a marker of the diet carrying it?
The magnesium-rich foods are whole grains, green leafy vegetables, nuts, beans, and cocoa — i.e. a whole-food, plant-rich dietary pattern (the same foods behind the DASH mineral story and potassium). The authors themselves cannot rule out that magnesium is a proxy: «we cannot exclude the possibility that other nutrients and/or dietary components correlated with dietary magnesium may have been responsible, either partially or entirely, for the observed associations». (Fang et al., 2016)
This is the component-vs-pattern problem in full: an observational dietary-magnesium gradient is not evidence that the magnesium atom is the active ingredient rather than the food matrix or the overall diet quality it indexes (). Consequence for the recommendation: eat more magnesium-rich whole foods is well-supported directionally; supplement magnesium to cut CVD/mortality is NOT what this evidence shows.
Dietary is not supplemental — a different exposure
This is dietary intake only. The paper cites separate trial evidence that oral magnesium supplements (>=4 months) improve insulin sensitivity and glucose control (Simental-Mendia, via Fang) — but that is a different exposure (isolate vs food matrix), not pooled here, and it reports a surrogate (glycaemia), not hard outcomes. No large RCT has raised magnesium intake to prevent CVD/T2D; the base is entirely observational. (Fang et al., 2016)
Measurement error and the null arms
Dietary magnesium is FFQ-self-reported, and the authors note «measurement error might occur in dietary assessment, which would likely bias true associations towards a null association» — so the CVD/CHD nulls and the mortality upper bound touching 1.0 are weak evidence of no gradient, not proof of none (Measurement Error in Dietary Assessment; attenuation-toward-null). (Fang et al., 2016)
Robustness notes
- Mortality is the weakest of the four positive findings: per-100mg RR 0.90 (0.81-0.99) with I2=62%, upper CI at 0.99, and it did not survive a subgroup/meta-regression cut where stroke incidence stayed inverse (0.92; 0.89-0.95) but mortality did not (RR 1.07; 0.90-1.28).
- Stroke is ischemic-driven (ischemic 0.93, 0.88-0.98; hemorrhagic null 0.97, 0.88-1.07).
- Heart failure is the largest per-increment effect (22%) but rests on 3 datasets from 2 cohorts — precise (I2=0) but narrow; non-linearity untestable.
- Publication bias: no significant evidence (funnel/Egger/Begg) across outcomes. NOS mean quality 8.2.
All figures in this section: (Fang et al., 2016)
Layer-1 placement (where this ranks)
A modifiable dietary exposure with a plausible, non-trivial relative signal on T2D and stroke — but (i) observational-only with an unresolved pattern-vs-component confound, (ii) no hard-outcome RCT, and (iii) absolute benefit unquantified. It is a refinement lever, not a big rock: for a reasonably healthy person, prefer magnesium-rich whole foods is subsumed by the broader whole-food / DASH-pattern recommendation that already carries potassium, fibre, and low-SFA benefits — magnesium does not add an independent, separately-actionable lever on this evidence.
Gaps (G)
- Does repleting magnesium (diet OR supplement) causally reduce hard cardiometabolic outcomes? No large hard-outcome RCT exists — the observational-to-causal gap is open (a genuine insufficient-evidence state, not a null).
- What is the shape of the T2D / stroke curve (knee location, minimum effective dose)? Non-linearity is flagged but unquantified here — needs the spline coordinates or a curve-shape SR.
- Absolute risk reductions by baseline-risk stratum — not derivable from this relative-only source.